Wegovy weight loss pills: what the oral tablet actually is and whether it could work for you

What the pill actually is — and how it differs from the injection you may already know

The weekly Wegovy injection has been available in the UK since 2023. The tablet version is genuinely different in how it gets into your body. Semaglutide on its own is broken down in the stomach before it can reach the bloodstream, so Novo Nordisk co-formulated it with a compound called SNAC, which temporarily raises local pH and allows the drug to cross the stomach lining. The result is a once-daily oral dose that activates the same GLP-1 receptors as the injection, slowing gastric emptying, reducing appetite and helping the body regulate blood sugar.

This is not a different drug, it is the same semaglutide molecule. The licensed maintenance dose for the tablet is 25 mg daily, which is not directly comparable to the 2.4 mg weekly injection figure; the oral route has lower and more variable bioavailability, so the milligram numbers differ substantially. If you want to compare the two forms in detail, the oral Wegovy overview sets them side by side. For now, the key point is that the mechanism is shared, the clinical pathway is separate, and neither form is available without a prescription following a clinical assessment.

One practical note: unlike the injection pens, which require refrigeration, the tablets sit at room temperature. No cold chain means simpler storage and no awkward conversations at airport security.

What the trial results showed, and what they did not promise

The OASIS 4 phase 3 trial followed 307 adults with obesity or overweight plus at least one weight-related condition, without type 2 diabetes, for 64 weeks. Participants using the Wegovy weight loss pill alongside lifestyle changes lost an average of around 13.6% of their body weight, compared with around 2.4% in the placebo group. Among those who adhered fully to treatment, the average reached approximately 16.6%. That fuller-adherence figure is worth treating carefully: it describes a specific subset of trial participants, not a typical result you should expect by default.

The most common side effects in the trial were gastrointestinal (nausea, vomiting, diarrhoea and constipation) reported by around 74% of participants on the pill versus 42% on placebo. Most were mild to moderate and settled as the body adjusted, particularly during the early escalation stages. If you are weighing up whether semaglutide pills for weight loss are the right fit for you, the semaglutide tablets page covers the side-effect profile in more depth, including what to watch for and when to contact your clinical team. The NHS tirzepatide and semaglutide medicines pages, and the MHRA's published guidance on GLP-1 medicines, are the definitive public-facing sources on safety and what to report.

Results from any clinical trial describe a population average. Your own response will depend on your starting point, any other medicines you take, how consistently you follow the dosing rules, and the lifestyle changes you make alongside treatment. No one can guarantee a specific outcome.

The one part of taking the pill people underestimate: the morning routine it requires

Oral semaglutide is absorbed in a narrow window. You take one tablet first thing in the morning, on a completely empty stomach, with a small sip of plain water, up to about 120 ml. Then you wait. At least 30 minutes must pass before any food, any other drink including coffee, or any other oral medicines. The tablet must be swallowed whole.

That 30-minute gap shapes your morning more than most people expect. Think of it as the tablet going in before the kettle goes on rather than with your first cup. For some people that discipline feels easy; for others, especially those whose mornings are rushed, it takes deliberate adjustment. If you are already taking medicines first thing (a thyroid tablet, a blood pressure pill) your prescriber needs to know, because the timing rules for oral semaglutide interact with those routines.

The injection, by contrast, is once weekly and has no food-timing restriction. If your mornings are reliably variable or you take several daily medications, that difference is worth raising during your consultation. You can read more about what the tablet involves day-to-day on the Wegovy pill for weight loss page.

Who this medicine is licensed for, and what happens next if you want to explore it

The MHRA licensed the Wegovy weight loss pill for adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, raised cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. The licence sits alongside a reduced-calorie diet and increased physical activity, the tablet supports those changes, not substitutes for them.

The oral tablet is not currently available on the NHS; a NICE appraisal would be required before NHS commissioning could begin. Private prescription is the route available now. If you are also curious about weight loss pills like Wegovy to understand how the options compare, or if you are wondering about the cost involved, the Wegovy pill cost page sets out what a private prescription typically includes and what to check for when comparing providers.

Eligibility is not just a BMI calculation. A prescriber looks at your full picture: current medicines, relevant medical history, contraindications, and whether the tablet or the injection is the more appropriate starting point. If you are already established on the 2.4 mg weekly Wegovy injection, MHRA guidance notes that moving directly to the 25 mg tablet may be possible subject to clinical assessment, but that transition is a clinical decision, not a self-directed switch.

At nume, a GPhC-registered Independent Prescriber reads every consultation personally; your answers go to a real clinician, not a screening algorithm. If the Wegovy weight loss pill looks like a reasonable fit for your situation, start your free consultation and our clinical team will work through it with you.